IPW)

Docket No.: OKA-0230

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Takashi Suzuki et al.

Application No.: 10/559,500

Confirmation No.: 1582

Filed: December 5, 2005

Art Unit: 1636

For: EXTRACT FROM CULTURED

MAMMALIAN CELL, PROCESS FOR PREPARATION THEREOF AND METHOD OF CELL-FREE PROTEIN SYNTHESIS

USING THE EXTRACT

Examiner: D. M. Sullivan

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith on Form PTO-1449 or PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR 1.56. Applicant respectfully requests that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 or PTO/SB/08 be returned in accordance with MPEP §609.

A copy of each listed document is being submitted to comply with the provisions of 37 CFR §§1.97 and 1.98

excluding a copy of U.S. patent or U.S. patent application publication as waived by the U.S. Patent and Trademark Office, since this application was filed after June 30, 2003 or has entered the national stage under 35 U.S.C. § 371 after June 30, 2003 (1276 OG 55).

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Application No.: 10/559,500 Docket No.: OKA-0230

☐ 1. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the present application. **No fee is required**. If, however, a first Office Action on the merits has issued, the Patent Office is authorized to charge \$180.00 under 37 CFR §§ 1.97 and 1.17.

2. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 18-0013 as needed to ensure consideration of the disclosed information.

Dated: August 27, 2007

Respectfully submitted,

By \_\_\_\_\_\_ Lee Cheng

Registration No.: 40,949

RADER, FISHMAN & GRAUER PLLC Correspondence Customer Number: 23353

Attorney for Applicant

PADEMARY

orm 1449/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 1 1

Complete if Known				
Application Number	10/559,500-Conf. #1582			
Filing Date	December 5, 2005			
First Named Inventor	Takashi Suzuki			
Art Unit	1636			
Examiner Name	D. M. Sullivan			
Attorney Docket Number	OKA-0230			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,461,609-B1	10-08-2002	Calhoun et al.	

FOREIGN PATENT DOCUMENTS							
	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY				
	ВА	WO-02/074940-A1	09-26-2002	Oncolytics Biotech Inc.		1	
	BB	WO-2004/101805-A1	11-25-2004	Axxima Pharmaceuticals AG		V	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Supplementary Partial European Search Report for EPO Application No. EP 04 74 5964 dated July 5, 2007 (5 pages)		
	СВ	First Office Action dated for May 11, 2007 from State Intellectual Property Office of People's Republic of China for China Patent Application No. 200480016278.2. Copies are provided in English (4 pages) & Chinese (3 pages), (7 pages total)		
	cc	CHIN J. ONCOL, September 2001, Volume 23, Number 5, Page 360, September 30, 2001 with an English Translation From China Science dated 7/24/2007, (5 pages),		
	CD	Marusic, A., et al., Croatian Medical Journal, "Radioimmunoassay Quantification of Intra- and Extracellular Interleukin 1 Alpha in Murine Macrophages, Osteoblastic Cell Line and Calvarial Cultures" by Croatian Medical Journal, Department of Medicine, Veteran Affairs Medical Center, Newington; University of Connecticut Health Center, Farmington, Connecticut, USA. Vol. 33 (4) pgs 207-212, 1992		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	
		<u> </u>

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.